A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants. This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts. For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.

NCT Number	NCT07347548
Lead Sponsor	Grünenthal GmbH
Conditions	Duchenne Muscular Dystrophy (DMD)
Enrollment	24 participants
Start Date	2026-01-06
Primary Completion	2026-06-09 (estimated)
Study Completion	2026-06-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-12